Adverse events related to cyclin dependent kinase 4/6 inhibitors: A real-world study based on the FDA Adverse Event Reporting System

Background: Multiple CDK4/6 inhibitors have been approved for the treatment of HR +/HER- advanced breast cancer. Nevertheless, there is currently a scarcity of safety reports on CDK4/6 inhibitors within large sample cohorts. Methods: To use the FDA Adverse Event Reporting System database to analyze adverse events associated with the three marketed CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib). We retrieved pertinent reports from 2004 Q1 to 2023 Q3. Four asymmetric analyses were utilized to assess signals. Results: A total of 459 positive signals were obtained at the preferred term level (146 positive signals for palbociclib, 68 positive signals for abemaciclib, 245 positive signals for ribociclib). Palbociclib-related adverse events were commonly fatigue, white blood cell count decreased, alopecia. Abemaciclib-related adverse events were commonly diarrhea, decreased appetite, dehydration. Ribociclib-related adverse events were commonly neutropenia, white blood cell count decreased and decreased immune responsiveness. Unexpected adverse events related to palbociclib included hot flush, bone marrow failure. Unexpected adverse events related to abemaciclib included myelosuppression, dehydration, and cystatin C increased. Unexpected adverse events related to ribociclib included decreased immune responsiveness, pleural effusion, atrioventricular conduction time shortened. Conclusion: Our research corroborates the typical adverse events linked to CDK4/6 inhibitors while highlighting potential safety concerns in their real-world clinical application.

Authors

Publication Details

Journal
Breast Care
Published
2026-11-18
DOI
https://doi.org/10.1159/brc/abrag015
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adverse events related to cyclin dependent kinase 4/6 inhibitors: A real-world study based on the FDA Adverse Event Reporting System

Shuhuai Wang, Yuting Li, Siqi Zhang
4 links
Breast Care
Advanced Breast Cancer Therapies
article

Adverse events related to cyclin dependent kinase 4/6 inhibitors: A real-world study based on the FDA Adverse Event Reporting System

Shuhuai Wang, Yuting Li, Siqi Zhang
article en

Abstract

Background: Multiple CDK4/6 inhibitors have been approved for the treatment of HR +/HER- advanced breast cancer. Nevertheless, there is currently a scarcity of safety reports on CDK4/6 inhibitors within large sample cohorts. Methods: To use the FDA Adverse Event Reporting System database to analyze adverse events associated with the three marketed CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib). We retrieved pertinent reports from 2004 Q1 to 2023 Q3. Four asymmetric analyses were utilized to assess signals. Results: A total of 459 positive signals were obtained at the preferred term level (146 positive signals for palbociclib, 68 positive signals for abemaciclib, 245 positive signals for ribociclib). Palbociclib-related adverse events were commonly fatigue, white blood cell count decreased, alopecia. Abemaciclib-related adverse events were commonly diarrhea, decreased appetite, dehydration. Ribociclib-related adverse events were commonly neutropenia, white blood cell count decreased and decreased immune responsiveness. Unexpected adverse events related to palbociclib included hot flush, bone marrow failure. Unexpected adverse events related to abemaciclib included myelosuppression, dehydration, and cystatin C increased. Unexpected adverse events related to ribociclib included decreased immune responsiveness, pleural effusion, atrioventricular conduction time shortened. Conclusion: Our research corroborates the typical adverse events linked to CDK4/6 inhibitors while highlighting potential safety concerns in their real-world clinical application.

Breast Care
Good health and well-being
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon